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Abstract
Background: Technological advancements of remote-monitoring used in clinical-care and research
require validation of model updates.
Objectives: To compare the output of a newer consumer-grade accelerometer to a previous model in
people with multiple sclerosis (MS) and to the ActiGraph, a waist-worn device widely used in MS
research.
Methods: Thirty-one individuals with MS participated in a 7-day validation by the Fitbit Flex (Flex),
Fitbit Flex-2 (Flex2) and ActiGraph GT3X. Primary outcome was step count. Valid epochs of 5-min
block increments, where there was overlap of 1 step/min for both devices were compared and summed
to give a daily total for analysis.
Results: Bland–Altman plots showed no systematic difference between the Flex and Flex2; mean step-
count difference of 25 more steps-per-day more recorded by Flex2 (95% confidence intervals (CI)¼ 2,
48; p¼ 0.04),interclass correlation coefficient (ICC)¼ 1.00. Compared to the ActiGraph, Flex2 (and
Flex) tended to record more steps (808 steps-per-day more than the ActiGraph (95% CI¼ –2380, 765;
p< 0.01), although the ICC was high (0.98) indicating that the devices were likely measuring the same
kind of activity.
Conclusions: Steps from Flex and Flex2 can be used interchangeably. Differences in total step count
between ActiGraph and Flex devices can make cross-device comparisons of numerical step-counts
challenging particularly for faster walkers.
Keywords: Physical activity, motor activity, accelerometry, multiple sclerosis, validation studies as topic
(mesh heading)
Date received: 1 May 2019; Revised received: 19 October 2019; accepted: 21 October 2019
Introduction
Ambulatory disability is a frequent and often devas-
tating consequence of multiple sclerosis (MS).1,2
People with MS are more sedentary than the general
population3–7 which can amplify already disabling
symptoms and increase the risk of sedentarism-
related morbidity.8,9 Remote activity monitoring
can be useful for documenting activity status for
clinical care by recording the amount of activity a
person actually performs in daily life rather than
what a person is capable of doing in a clinic
evaluation.10,11
ActiGraph accelerometers are widely used in MS
research, accounting for 75% of 61 articles reporting
on 24 hours and <1 month of continuous physical
activity monitoring in MS.12,13 The waist-worn
ActiGraph may be impractical for longer-term con-
tinuous use (i.e. year-long) due to inconvenience,
expense and technical barriers. Ankle-worn devices
such as the StepWatch have similar limitations.
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Unobtrusive, commercially available, wrist-worn
devices could be an alternative for continuous,
longer-term monitoring of physical activity. In
healthy adults, many such wearable devices have
been validated against manual or video recording
during treadmill training, and at home (over c. 7
days) as accurate measures of step count.14–18
Manufacturers often do not share the hardware or
algorithm updates of the frequently changing wear-
able devices with the consumer (or researcher), nor
is validation data readily available. Hence, in longi-
tudinal studies where device loss and replacement
are inevitable, it is important to ensure that newer
generation devices have output metrics comparable
to the original device used at study initiation.
For example, the Fitbit Flex 2 (Flex2) replaced the
Fitbit Flex (Flex), a widely used wrist-worn acceler-
ometer. The Flex2 is waterproof (reducing risk of
not being re-donned post-ablution and thereby
could increase adherence) and records swimming –
an important option for exercise in some individuals
with MS due to pervasive heat sensitivity.19–21 In
this study, we sought to (a) compare the output
from the Flex and ActiGraph GT3X against
manual step-counting 22 over 2 min in the clinic,
and (b) compare the outputs from the Flex2 to that
of the Flex, and ActiGraph at home over 7 days. The
ActiGraph was selected as a reference because of its
widespread use in MS studies.
Material and methods
Participants
Individuals enrolled in the FITriMS cohort study
(Fitbit remote monitoring in MS)22,23 were assessed
at study entry (including a 2-min walk test
(2MWT)). Participants were invited to participate
in a 7-day home validation of Flex against an
ActiGraph GT3X (Group 1) once they had complet-
ed >3 months,24 and the Flex2 after >10 months in
FITriMS (Group 2). Individuals with relapsing–
remitting or progressive forms of MS from the
UCSF MS Center clinic were prospectively recruited
between July 2015 and April 2016. Inclusion criteria
were: (a) a definite diagnosis of MS, defined by
2010 International Panel criteria;25 (b) 18 years
of age; (c) ability to walk for at least 2 min with
or without an assistive device; (d) relapse free for
30 days prior to study entry; (e) Wi-Fi Internet
access and the ability to follow instructions for tech-
nology maintenance. Participants were excluded if
they had major musculoskeletal (e.g. recent broken
leg), cardiovascular or respiratory comorbidities
(e.g. congestive heart failure) that could interfere
with physical activity and potentially bias or obscure
results. The definition of the 2014 Advisory
Committee on Clinical Trials in MS Committee
was employed for the characterization of relapsing
and progressive MS phenotypes.26 The UCSF IRB
approved the study protocol. All participants provid-
ed written informed consent.
Study procedures
Neurologists evaluated disability using the
Expanded Disability Status Scale, EDSS.27
Step count measurement techniques included:
• Manual step counting: research personnel
recorded actual steps the participant took over a
2MWT.
• ActiGraph GT3X (Manufacturing Technology,
Inc., FL, USA): this contains a triaxial accelerom-
eter, is worn on an elastic band around the waist
and is validated as a measure of walking behav-
iour in individuals with MS.28,29 For this study
the accelerometer signals were set at 30 Hz and
10-second epochs. The data were retrieved from
the ActiGraph via a direct USB 2.0 connection
and downloaded using ActiLife v6.13.2 software.
A low frequency extension filter was applied, as
per the manufacturer’s guideline.30
• Fitbit Flex (Flex) (Fitbit, CA, USA): Flex con-
tains a tri-axial accelerometer within a discreet
bracelet worn around the wrist.19 The Flex
records step count as the main outcome and was
previously validated in MS.22 Commercial pro-
duction of the Fitbit Flex was discontinued, and
this model is being replaced with the Fitbit Flex 2.
• Fitbit Flex 2 (Flex2) (Fitbit, CA, USA): Flex2
contains a tri-axial accelerometer within a dis-
creet bracelet around the wrist. The main outcome
metric is steps per epoch (i.e. minute or day). The
device can be worn at all times (waterproof up to
100 m).
Both the Flex and Flex2 synchronize with either
smartphone applications (via Bluetooth) or a com-
puter application (via USB dongle). The research
team purchased the devices without financial sup-
port from device manufacturers.
At study entry, step count was compared between
manual, Flex and ActiGraph over a 2MWT.
For the 7-day home comparison in the two groups,
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eligible participants were mailed a package contain-
ing: (a) a fully charged and activated ActiGraph
accelerometer (set to record for 7 3 days); (b) a
Flex2 (only Group 2) device pre-set up with an
anonymous Gmail account different from their orig-
inal Flex account to ensure data quality; (c) written
instructions; and (d) a pre-paid envelope to return
the ActiGraph and Flex2 at the end of the monitoring
period. An electronic message was sent with detailed
instructions and a reminder to continue wearing their
Flex simultaneously. Participants were instructed not
to change their normal daily activities and to wear
the Flex2 on the same wrist as the Flex (non-domi-
nant). The ActiGraph was worn on an elastic belt
around the waist over their non-dominant hip.
The Health eHeart Study clinical research platform
(https://www.health-eheartstudy.org/) was used for
electronic consent and remote Fitbit data collection.
Participants gave authorization to link their Fitbit
accounts for the study to recover data for research
purposes. The Health eHeart database collected and
stored the data through an application-programming
interface.
Statistical analysis
Wear-time validation for the ActiGraph was gener-
ated using 60-second epochs.31 The Troiano (2007)
wear-time validation parameters were used.32,33 At
least 10 hours of valid wear time per day and 3 days
of valid data were required for comparative assess-
ment.34 Interclass correlation coefficients (ICCs)
with 95% confidence intervals (CIs) were
calculated.
Absolute step count was compared between devices
over the 2MWT. To calculate steps per day, at home,
valid measurements were defined as continuous 5
minute increments, or ‘blocks’, when there was
overlap of at least 1 step/min for the two devices
being compared. These blocks were then summed
to give daily totals (Supplemental Figure S1). For
this analysis, we compared blocks rather than total
daily averages, since there were times where one
device was used for higher intensity physical activity
(running, swimming) while the other was not worn,
even on days that were deemed valid. With this ana-
lytical method, the intervals compared included only
times when both devices were being worn
simultaneously.
We compared step counts among the measurement
devices using the Bland–Altman approach35 and
paired t-test to determine the mean difference. The
modified limits of agreement method was applied on
the repeated measurements to compare the repeat-
ability of the two raters.35 Modified Bland–Altman
(with correction) was used when there was a linear
relationship between the mean difference of the step
counts recorded by the devices and the average of
the step counts from the devices being com-
pared.36,37 Paired two-sample t-tests assuming
equal variance were used to determine if potential
covariates (sex or disease subtype) were factors in
the difference between step count measures. The
‘leave-one-out’ method38 was used to assess for dif-
ferential bias across the disability spectrum. The
model was then trained on each EDSS group
subset to determine the relationship between the
step-count difference and the average step count on
the two devices. A linear regression model was per-
formed to examine the effect of the EDSS groups on
the rate of step count difference change over the
average of step count (slope).
R software calculated statistics and generated fig-
ures;39 p-value< 0.05 was considered significant.
Results
Sixty-one participants were included in comparisons
between Flex and ActiGraph to manual step count-
ing (the gold standard for this study) during the
2MWT (Table 1).22,24 Bland–Altman plots showed
no systematic bias between devices. Compared to
manual counts, the ActiGraph tended towards
under-record steps whereas the Fitbit over counted
compared to ActiGraph for lower daily steps
(Supplemental Figure S2). There was no systematic
bias between Fitbit and manual counts. Over 2MWT,
ICCs were moderate–high between ActiGraph and
Flex (0.59, 95% CI¼ 0.40–0.73. Mean differ-
ence¼ –6.03), Flex and manual (0.69, 95%
CI¼ 0.53–0.80. Mean difference¼ 9.75) and
ActiGraph and manual (0.76, 95% CI¼ 0.63–0.85.
Mean difference¼ 15.79). Covariates (sex, disease
subtype and age group) did not affect the results.
Thirty-six individuals participated in the home com-
parison of the Flex2 and ActiGraph over 7 days. Five
participants returned the ActiGraph with data for
different days than was recorded for the Flex2 and
were excluded. No participants were excluded due to
cardiovascular or musculoskeletal comorbidities.
Median EDSS at study entry was 4.0 (Interquartile
range, IQR 2.5–6.0); 17 (58%) were women; and 16
(52%) had a diagnosis of relapsing MS (Table 2).
Sample size for each comparison, after quality con-
trol and performing the ‘block’ analysis for the daily
Block et al.
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step count totals were: 22 for the ActiGraph/Flex2,
18 for Flex/Flex2 and 20 for the ActiGraph and Flex.
Including unique (different) individuals from Group
1 increased the sample to 33. Subjects reported that
missing data for Flex and Flex2 occurred due to dif-
ficulties remembering to sync both devices on
separate accounts. Missing ActiGraph data was due
to forgetting or not wanting to don the device.
Flex2 averaged 808 more steps-per-day than the
ActiGraph (Bland–Altman: 95% CI¼ 670, 946;
p< 0.01). However, when we used modified
Table 2. Group 2: demographic data for 7-day home-environment step count comparisons (Flex, Flex2 and ActiGraph).
Demographics All ActiGraph v. Flex2 Flex2 v. Flex ActiGraph v. Flex
Sample size: (n)
All participants 31 22 18 20
Progressive MS 15 11 10 11
Relapsing MS 16 11 8 9
Female (n (% of MS subgroup))
All participants 17 (58.1) 12 (54.5) 9 (50.0) 9 (45.0)
Progressive MS 6 (33.3) 5 (45.5) 4 (40.0) 3 (27.3)
Relapsing MS 12 (66.6) 7 (63.6) 5 (62.5) 6 (66.7)
p-value 0.9779 0.669 0.635 0.190
Average age (years (SD))
All participants 53.4 (11.7) 53.4 (13.1) 54.4 (10.5) 55.2 (10.6)
Progressive MS 59.4 (7.5) 59.8 (8.3) 58.3 (6.6) 60.0 (6.5)
Relapsing MS 46.9 (12.0) 46.9 (14.1) 49.5 (12.8) 49.3 (12.0)
p-value <0.001 0.009 0.059 0.011
EDSS at baseline (median (range))
All participants 4.0 (0.0–6.5) 4.0 (0.0, 6.5) 4.0 (0.0, 6.5) 4.0 (0.0, 6.5)
Progressive MS 6.0 (3.5–6.5) 6.0 (3.5, 6.5) 6.0 (3.5, 6.5) 6.0 (3.5, 6.5)
Relapsing MS 2.0 (0.0–6.0) 2.0 (0.0, 5.0) 1.8 (0.0, 4.0) 2.0 (0.0, 4.0)
p-valuea <.001 <0.001 <0.001 <0.001
Disease duration (median (IQR))
All participants 17.5 (8.5–23.0) 11.5 (5.2, 21.0) 11.5 (5.2, 21.0) 13.0 (5.8, 23.2)
Progressive MS 19.5 (9.0–25.0) 17.0 (6.5, 28.5) 19.5 (6.8, 31.2) 17.0 (7.5, 29.5)
Relapsing MS 13.0 (7.5–22.0) 10.0 (4.5, 13.5) 9.5 (4.8, 13.2) 10.0 (5.0, 14.0)
p-value 0.232 0.07 0.056 0.097
Daily step count: (mean (SD)) ActiGraph/Flex2 Flex2/Flex ActiGraph/Flex
All participants N/A 2148 (2292)/2880 (2581) 3089 (2719)/3060 (2691) 2125 (2278)/2908 (2531)
Progressive MS N/A 1396 (2119)/1800 (2275) 2016 (2616)/1999 (2603) 1501 (2189)/2066 (2308)
Relapsing MS N/A 2900 (2302)/3879 (2573) 4431 (2337)/4387 (2292) 2889 (2269)/3936 (2528)
p-value 0.111/0.054 0.042/0.042 0.165/0.084
MS: multiple sclerosis; SD: standard deviation: EDSS: Expanded Disability Status Scale; IQR: interquartile range.
ap-value is the difference in demographics between participants with progressive MS and relapsing MS.
Table 1. Group 1: demographic data for step count comparison over a clinic-based 2-Minute Walk Test (2MWT)
(Manual, Fitbit Flex and ActiGraph), and 7-day home-environment step count comparisons (Fitbit Flex and
ActiGraph). (Adapted from Block 2016.24)
2MWT Home comparison
Sample size (n) 61 20
Female (n (%)) 44 (72) 14 (70)
Age in years (mean (SD)) 50 (14.4) 54 (11.4)
EDSS (mean (range)) 4.0 (0.0–6.5) 4.0 (0.0–6.5)
EDSS  4 (n (%)) 34 (55.7) 12 (60)
Relapsing MS (n (%)) 42 (69) 10 (50)
SD: standard deviation; EDSS: Kurtzke Expanded Disability Status Scale.
Multiple Sclerosis Journal—Experimental, Translational and Clinical
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(corrected) Bland–Altman there was a high percent-
age of data points (96%) within the 95% limits of
agreement, indicating a better fit (Figure 1a,
Supplementary Table 1B). A similar trend was
seen between Flex and ActiGraph (mean difference:
873 per day. 95% CI¼ 724, 1023; p< 0.01)
(Figure 1b). The percentage of data points within
the 95% limits of agreement increased from 93 to
96% using the modified Bland–Altman, also denot-
ing a better fit with this method (Figure 1b). No
systematic difference was seen in the modified
Bland–Altman plots for the Flex v. Flex2 (mean dif-
ference: 25 steps/d more recorded by the Flex2
(95% CI¼ 2, 48; p¼ 0.04)) (Figure 2). The percent-
age of data points within the 95% limits of agree-
ment decreased (95 to 92%) when using the
modified Bland–Altman, revealing that this correc-
tion did not produce a better fit.
ICCs were high for all comparisons: ActiGraph v.
Flex2 (0.98 (95% CI¼ 0.97–0.99)), ActiGraph v.
Flex (0.98 (95% CI¼ 0.97–0.98)) and Flex v. Flex
2 (1.0 (95%CI¼ 1.0–1.0)) (Table 3). A larger dis-
crepancy was observed between devices with greater
daily steps (Figures 1 and 2) and lower walking dis-
ability. The difference between ActiGraph and
Flex2/Flex, was greater for individuals who took
more steps/d (mean difference –387 (95% CI¼ –
491, –282) below the cohort median v. –1229
(95% CI¼ –1439, –1019) above it)
(Supplementary Table 2). Discrepancy was negligi-
ble between Flex and Flex2 (–10 steps difference
(95% CI¼ –23, 4) below the cohort median, and
59 step difference (95% CI¼ 16, –102) above).
Between the Flex and ActiGraph, the effect of dis-
ability (increased EDSS score) on the rate of step-
count difference change over the slope was not sig-
nificant, although trended towards decreasing
(n¼ 33, b¼ –0.019, p¼ 0.229) (Supplementary
Figure S3).
The discordance in steps recorded was greater for all
comparisons in individuals with relapsing MS
(Table 4). The Flex and Flex2 showed the lowest
discordance in step count for both disease
subtypes (mean difference progressive: 3, p¼ 0.72
(95% CI¼ –14, 19) and relapsing: 49, p¼ 0.034
(95% CI¼ 4, 94)). Between genders, significant dif-
ference in step count was observed between Flex2
and Flex for men (mean difference: 56 steps/day,
95% CI¼ 29, 82; p< 0.01) but not women (mean
difference: 3 steps/day, 95% CI¼ –31, 38;
p¼ 0.848). ActiGraph measured fewer steps than
Flex2 in both women (mean difference: –830
steps/day, 95% CI¼ –1022, –638; p< 0.01) and
men (mean difference: –783 steps/d, 95% CI¼ –
988, –578; p< 0.01). Modified Bland–Altman plots
presented a superior fit, improving the percentage of
people within the 95% limits of agreement in
women from 93 to 99%. Similar results were
found for ActiGraph and Flex comparisons.
Discrepancy between Flex and Flex2 was greater in
individuals with lower disability (EDSS< 4.0, mean
difference: 49 steps/day, 95% CI¼ 4, 94; p¼ 0.034)
than those with greater disability (EDSS 4.0, mean
difference: 3 steps/d, 95% CI¼ –14 steps/day 19;
p¼ 0.721). Greater discrepancy was seen between
ActiGraph and Flex2 for individuals with lower dis-
ability (EDSS< 4.0: mean difference: –1086 steps/d,
Figure 1a. ActiGraph and Flex2 (modified Bland–Altman
plot).
Figure 1b. ActiGraph and Flex (modified Bland–Altman
plot). The solid lines represent the mean differences
between the measures and the dashed horizontal lines
represent mean differences 2 standard deviations. Each
solid point corresponds to a separate individual, for a
separate day. The solid lighter grey lines indicated where
‘0’ difference between the measures would lie. The grey
dashed lines are the 95% limits of agreement. The histo-
grams on the top and right depict the distribution of the
data.
Block et al.
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95% CI –1303, –868; p< 0.01) than higher disabil-
ity scores (EDSS 4.0: mean difference: –503 steps/
day, 95% CI¼ –638, –368; p< 0.001). The
ActiGraph and Flex comparisons yielded similar
results.
Discussion
Consistent with previous literature,13,16,40 the
ActiGraph tended to under-record steps when
fewer steps were taken (slower walking), in the
clinic test and also during the home validation
(7 d). Greater differences between ActiGraph and
Flex (and Flex2) were observed in individuals
taking greater steps/day, with lower disability, who
were men, and were diagnosed with Relapsing MS.
The difference was not related to disability status,
although a larger sample may show a small negative
differential bias with increasing EDSS scores, inde-
pendent of daily steps. In light of these results,
researchers should be cautious when choosing what
device to use for measuring step count in people
with faster walking speeds.
Our previously reported results on Group 1 (n¼ 20)
illustrated that Flex recorded 1132 steps/d more than
ActiGraph (95% CI¼ 500–1763).24 However, the
mean difference was small (c. 70 steps) for days
with low steps (<3000 steps) and increased
(c. 2400 steps difference) as daily steps increased
(>3000 steps/day).24 The current analysis confirms
these results.
This study describes a general method for corrobo-
rating measurements of daily step counts captured
by remote activity monitoring. The correlation
between the Flex and Flex2 step counts
demonstrates that step-count data captured by these
devices is essentially identical (ICC¼ 1.0, p< 0.01)
and can be used interchangeably for remote step
count monitoring in individuals with MS. It is
likely that other devices using the identical tri-
axial accelerometer will yield similar results.
However, because manufacturers do not provide
hardware or algorithm updates to consumers, it is
necessary to establish methods to compare newer
to older models thereby ensuring data quality and
integrity.
Because prior research indicated greater percentage
use of the wrist-worn accelerometers compared to a
waist-worn ActiGraph,22,24 we opted for a ‘blocked’
times approach to compare the devices and remove
potential bias from individuals wearing one device
more. Other studies have used a summative
approach,13 however here we selected the blocked
approach to favour actual wear-time when all devi-
ces were being used concurrently.
The difference between the Flex and Flex2 was neg-
ligible (the Flex2 recorded an average increase of 25
Figure 2. Flex2 and Flex (Bland–Altman Plot). The solid
line represents the mean difference between the measures
and the dashed horizontal lines represent mean difference
2 standard deviations. Each solid point corresponds to a
separate individual, for a separate day. The solid lighter
grey line indicated where ‘0’ difference between the
measures would lie. The grey dashed lines are the 95%
limits of agreement. The histogram on the top and right
depicts the distribution of the data.
Table 3. Interclass correlation coefficients (ICCs) and average differences in steps recorded between mea-
surement techniques during seven days of home activity monitoring (group 2).
ActiGraph – Flex2 Flex2 – Flex ActiGraph – Flex
Sample size (n) 22 18 20
ICC 0.98 1.00 0.98
(95% confidence interval) (0.97, 0.99) (1.00, 1.00) (0.97, 0.98)
Average difference in steps
recorded per devicea
–808 25 –873
aA negative value signifies that the first step counting technique (in the header) measured fewer steps; conversely, a
positive sign denotes that the first technique measures more steps than the comparator.
Multiple Sclerosis Journal—Experimental, Translational and Clinical
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steps/d than the Flex). However, both Flex and Flex2
wrist-worn devices recorded a significantly greater
number of steps than the waist-worn ActiGraph
GT3X (on average an increase of 873 and 808
steps/d, respectively). Notably, 96% of individuals
measured steps were within the 95% CIs. This
observation indicates that wrist-worn and waist-
worn devices are measuring the same activity but
are judging what constitutes a valid step differently,
with the ActiGraph being more conservative. A
study comparing the ActiGraph (GT3Xþ) and the
StepWatch observed high accuracy for both devices
at fast and comfortable walking speeds over a mod-
ified 6-Minute Walk Test, but showed discrepancies
(ActiGraph under-recording compared to the
StepWatch) at slower speeds and greater ambulatory
disability.13
The question remains: is Fitbit over-counting or is
ActiGraph under-recording? For in-clinic assess-
ments, what constitutes a step is relatively obvious
and the participant is fully aware that they are being
observed. Walking at home is less predictable in
ways that may affect how steps are counted. It is
possible that the ActiGraph may not have recorded
some activity as full steps whereas the Flex and
Flex2 did. The Flex and Flex2, on the other hand,
may record other body movements as steps, because
these devices are worn around the wrist. Thus the
term ‘step count’ is potentially misleading. It is pos-
sible that wrist-worn devices compute higher daily
steps compared to the waist-worn ActiGraph
because they count movements that may not consti-
tute full-length strides as steps. If so, then it is pos-
sible that wrist-worn devices may be more sensitive,
and possibly more accurate for overall daily physical
activity and function. Weikert et al., proposed that
ActiGraph measures ‘walking mobility’ rather than
physical activity when worn around the waist in indi-
viduals with MS.41
These data illustrate the importance of disease and
clinical context specific validation of activity moni-
toring devices for research and clinical care. There is
a growing trend of using wearables for health and
remote objective monitoring to obtain large amounts
of data from people in their daily life. Data from
people outside of the clinic-setting give a more
holistic view of their function, and may provide clin-
ical trials with more sensitive measures of real-world
disability worsening potentially over shorter study
durations than traditional performance-based or
patient-reported measures. Further study is ongoing
to address what other information can be obtained
from these wearable devices (i.e. min/min or active
v. sedentary bouts) and that may be useful to evalu-
ate activity in the home environment. For example,
changes outside of a pre-determined limit could
Table 4. Table of Bland–Altman results for all participants and separated into multiple sclerosis subtype
(relapsing and progressive) in Group 2.
Bland–Altman (correlation within Subject) % within 95% limits
of agreement
Mean difference
(95% confidence
intervals) p-valuea
Difference
 average
(slope, p-value)
(% within modified
95% limits of
agreement)b
Entire cohort
ActiGraph v. Flex2 –807.8 (–945.7, –669.9) <0.01 –0.136, <0.001 94 (96)
ActiGraph v. Flex –873.4 (–1022.8, –724.1) <0.01 –0.122, <0.001 93 (96)
Flex2 v. Flex 25.0 (1.7, 48.0) 0.036 0.013, 0.001 95 (92)
Progressive MS
ActiGraph v. Flex2 –545 (–722, –369) <0.01 –0.075, 0.03 91 (91)
ActiGraph v. Flex –625 (–818 –432) <0.01 –0.06, 0.111 92 (92)
Flex2 v. Flex 3 (–14, 20) 0.72 0.008, <0.01 93 (89)
Relapsing MS
ActiGraph v. Flex2 –1000 (–1191, –809) <0.01 –0.151, <0.001 93 (97)
ActiGraph v. Flex –1066 (–1276, –857) <0.01 –0.147, <0.01 94 (97)
Flex2 v. Flex 49 (4, 93) 0.034 0.015, 0.071 95 (91)
ap-value from paired t-test.
bModified Bland–Altman was used when there was any relationship between the mean and standard deviation of the
differences and the magnitude of the measurements.
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serve as an early warning sign perhaps prompting the
healthcare team to action. To address the discrepan-
cy between the Flex devices and the ActiGraph in
greater steps/d and lower disability, studies using
other, perhaps more sensitive activity monitors (i.e.
StepWatch) are needed.
Study limitations
Although disability score was not found to have a
sytematic effect on differential bias, given the
sample size larger studies should confirm these
results in a similarly wide range of disability. This
would increase generalizability across the spectrum.
Secondly, there may have been some ‘reactivity’ due
to the short validation time (7 d), although we did
not observe any reactivity in our larger cohort study
when wrist-worn devices were introduced.22 Thirdly,
the waist-worn ActiGraph appears to be less sensi-
tive to measurement of steps in more disabled per-
sons and perhaps ankle-worn devices (such as
StepWatch, which was not used in this study)
could provide another perspective on what wrist-
worn devices are actually measuring. For the goal
of this analysis, the block-time approach was specif-
ically selected in order to compare measurement of
all devices when they were actually being worn
simultaneously. However, the block-time approach
does not account for differences in total daily
device usage and therefore would not capture differ-
ences in wearability over the course of a valid day
that could bias results depending on the research
question. As a consequence, comparison of steps
using the block time method to the daily average
method may not be easily interpretable.
Conclusions
This manuscript presents a cross-validation method-
ology for remote activity monitoring devices. The
Flex and Flex2 models of consumer-grade acceler-
ometer, Fitbit, can be used interchangeably, howev-
er, caution should be exercised when using these
devices with people who walk many steps per day
or have lower levels of disability. Wearable devices,
marketed for consumers rather than research, can be
useful for longer-term studies as adherence is likely
to be higher, albeit at the potential cost of ‘exact step
count’ and detailed gait analysis.
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